Literature DB >> 29684293

Serological survey of measles immunity in the Czech Republic, 2013.

Hana Tomášková1,2, Hana Zelená1, Alena Kloudová1, Ivan Tomášek1.   

Abstract

OBJECTIVES: The aim of the serological survey of measles was to obtain information on the prevalence of antibodies against measles and to verify the effectiveness of vaccination in the Czech population in order to protect public health.
METHODS: The serological survey was carried out in the Czech Republic in 2013. Antibodies against measles were tested in 3,111 serum samples of participants aged 1-64 years. Serum samples were tested for the presence of immunoglobulin G (IgG) antibodies by enzyme immunoassay (EIA). The vaccination status assessment was based on the medical documentation. Seroprevalence differences were evaluated by sex and age using the Pearson's χ2 test at 5% significance level.
RESULTS: The overall seroprevalence reached 93.0% (2,893/3,111) (95% CI 92.0-93.9). No statistically significant difference was found between men and women (p=0.724). A lower seroprevalence was identified in the first age group (1-year old children) 62% (62/100), as the vaccination has not yet been completed in this age group. The second lowest seroprevalence 80.4% (160/199) was identified in the age group of 35-44 years. The highest seroprevalence 97.7% (387/396) (95% CI 95.7-99.0) was in the population with naturally-induced immunity (age above 45 years). In the individuals with two doses seroprevalence reached 94.1% (2,081/2,212) (95% CI 93.0-95.0). The level of IgG antibodies decreased in persons above 7 years of age.
CONCLUSIONS: Based on the results of the serological survey carried out in 2013 in the Czech Republic, it has been decided to postpone the second MMR (measles, mumps and rubella) dose to the age of 5-6 years. Copyright© by the National Institute of Public Health, Prague 2018.

Entities:  

Keywords:  measles; serological survey; seroprevalence; vaccination

Mesh:

Substances:

Year:  2018        PMID: 29684293     DOI: 10.21101/cejph.a5251

Source DB:  PubMed          Journal:  Cent Eur J Public Health        ISSN: 1210-7778            Impact factor:   1.163


  8 in total

1.  Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018 - 2019 outbreak.

Authors:  Ravit Bassal; Victoria Indenbaum; Rakefet Pando; Tal Levin; Eilat Shinar; Doron Amichay; Mira Barak; Anat Ben-Dor; Adina Bar Haim; Ella Mendelson; Dani Cohen; Tamy Shohat
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

2.  Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination.

Authors:  Sebastian Funk; Jennifer K Knapp; Emmaculate Lebo; Susan E Reef; Alya J Dabbagh; Katrina Kretsinger; Mark Jit; W John Edmunds; Peter M Strebel
Journal:  BMC Med       Date:  2019-09-25       Impact factor: 8.775

3.  Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.

Authors:  Í Ödemiş; Ş Köse; Í Akbulut; H Albayrak
Journal:  Rev Esp Quimioter       Date:  2019-10-23       Impact factor: 1.553

4.  Antibodies against measles and rubella virus among different age groups in Thailand: A population-based serological survey.

Authors:  Nasamon Wanlapakorn; Rujipat Wasitthankasem; Preeyaporn Vichaiwattana; Chompoonut Auphimai; Pornsak Yoocharoen; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

5.  Seroprevalence of Measles Antibodies in the Population of the Olomouc Region, Czech Republic-Comparison of the Results of Four Laboratories.

Authors:  Michal Krupka; Tereza Matusu; Helena Sutova; Katerina Wezdenkova; Renata Vecerova; Yvona Smesna; Milan Kolar; Hana Bilkova Frankova; Jana Krivankova; Miroslav Jorenek; Zdenek Novak; Milan Raska; Ondrej Holy
Journal:  Vaccines (Basel)       Date:  2022-01-25

6.  A Serosurvey Identifying Vulnerability to Measles in Health Care Workers. A Hospital-Based Prospective Seroprevalence Study.

Authors:  Jana Malinová; Marek Petráš; Alexander M Čelko
Journal:  Int J Environ Res Public Health       Date:  2020-06-12       Impact factor: 3.390

7.  Seroprevalence of IgG antibodies against measles in a selected Polish population - do we need to be re-vaccinated?

Authors:  Justyna Holka; Katarzyna Pawlak; Olga Ciepiela
Journal:  Cent Eur J Immunol       Date:  2020-01-20       Impact factor: 2.085

8.  [Seroprevalence of antibodies against measles virus in Galicia: trends during the last ten years depending on age and sex].

Authors:  J J Costa-Alcalde; R Trastoy-Pena; G Barbeito-Castiñeiras; D Navarro de la Cruz; B Mejuto; A Aguilera
Journal:  Rev Esp Quimioter       Date:  2020-03-02       Impact factor: 1.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.